Proteolysis targeting chimeric-based technology in myeloma and lymphoma
Proteolysis-targeting chimeras (PROTACs) leverage the ubiquitin-proteasome system to selectively degrade oncogenic proteins, including such previously seen as undruggable. Recent preclinical studies indicate that PROTACs may come as novel therapeutic strategy in lymphoma and myeloma. Indeed, preclinically, PROTACs have high efficacy and remarkable selectivity, favorable safety profile and lower toxicity compared to conventional therapies. Their catalytic, reusable mechanism enables drug dosing and offers the perspective of a long-term low dose treatment. PROTACs demonstrated their ability to overcome drug resistance by targeting and degrading overexpressed or mutant proteins, which are responsible for refractory disease. This review aims to offer a comprehensive evaluation of the current existing PROTACs that have been tested in Lymphoma and Myeloma, to highlight the need for drug optimization and further translational research that could translate PROTACs to clinical trials.
Authors
- Diana Cenariu (ORCID: https://orcid.org/0000-0002-1024-1479)
- Diana Gulei (ORCID: https://orcid.org/0000-0002-3030-8626)
- H. Einsele
- Dávid Kegyes (ORCID: https://orcid.org/0000-0002-6252-6281)
- Raluca Munteanu (ORCID: https://orcid.org/0000-0003-0617-2084)
- Aaron Ciechanover (ORCID: https://orcid.org/0000-0001-9184-8944)
- Mădălina Nistor (ORCID: https://orcid.org/0000-0002-5626-6911)
- Sebastian Kobold
- Ciprian Tomuleasa (ORCID: https://orcid.org/0000-0002-5770-7811)
- Andrei Ivancuta
- Adrian Bogdan Tigu
- Anca Dana. Buzoianu
- Massimo Federico
Institutions
- University of Modena and Reggio Emilia (IT)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca (RO)
- Rappaport Family Institute for Research in the Medical Sciences (IL)
- German Marine Research Consortium (DE)
- Universitätsklinikum Würzburg (DE)
Publication Details
- Journal
- Molecular Cancer Therapeutics
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1158/1535-7163.mct-25-1148
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Israel Cancer Research Fund
- Melanoma Research Alliance
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Ministerul Cercetării, Inovării şi Digitalizării
- European Commission
- Deutsche Forschungsgemeinschaft
- Israel Science Foundation
- Ludwig-Maximilians-Universität München
- Deutsche Krebshilfe
- HORIZON EUROPE Framework Programme
- Elitenetzwerk Bayern